Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

medicines

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

US lawmakers pass new bill to speed up drug reviews

FDA will also need to take the views of patients into greater consideration under new plans

- PMLiVE

George Freeman re-appointed as UK life science minister

Industry welcomes his continuation in this pharma-focused role

- PMLiVE

Is a UK market access shake-up on the cards?

Former coalition government health minister Paul Burstow tells PMLiVE that NICE, QALY and broader issues of market access in England are all being put under review

ABPI London offices

Pharma must engage on the affordability question, says ABPI

UK pharma trade body says the industry must be willing to discuss drug pricing

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Access – the only thing that matters

Our job, at its very core, is to get our medicines into the hands of patients

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

Anticipating the future in healthcare

New technologies will be key drivers for change

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

Transforming times at AstraZeneca

Lisa Anson, the company’s UK and Ireland president, on AZ's future direction

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links